ArticleAmerican journal of translational research2016
Grb2-associated binder-2 gene promotes migration of non-small cell lung cancer cells via Akt signaling pathway.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Identifying expression and DNA methylation biomarkers for lung adenocarcinoma risk in East Asia.Journal of the National Cancer Institute · 2026Article
- Comprehensive analysis of the potential mechanism of gansui in blocking non-small cell lung cancer progression.Pharmaceutical biology · 2025Article
- Androgen Receptor Promotes Lung Cancer Metastasis by Modifying the miR23a-3p/EPHB2 Pathway.Current medical science · 2024Article
- An analysis of the role of GAB2 in pan-cancer from a multidimensional perspective.Discover oncology · 2024Article
- MicroRNA‑373‑3p inhibits the proliferation and invasion of non‑small‑cell lung cancer cells by targeting the GAB2/PI3K/AKT pathway.Oncology letters · 2024Article
- RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma.Cell communication and signaling : CCS · 2023Article
- Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.Journal for immunotherapy of cancer · 2022Article
- miR-183-5p Inhibits Occurrence and Progression of Acute Myeloid Leukemia via Targeting Erbin.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer.Oncology letters · 2018Article
- GAB2 Amplification in Squamous Cell Lung Cancer of Non-Smokers.Journal of Korean medical science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early stages of non-small cell lung cancer (NSCLC) can be successfully treated by surgical resection of the tumor, but there is still no effective treatment once it is progressed to metastatic phases. Investigation of NSCLC cancer cell migration, metastasis and development of strategies to block this process is essential to improve the disease prognosis. In the present study, we found that GRB2-associated-binding protein 2 (Gab2) is involved in the migration of NSCLC cells and demonstrated that Gab2 disruption impairs NSCLC cells migration. The requirement of Gab2 in the migration of NSCLC was further confirmed by gene silencing in vitro. In corresponding to this result, over-expression of Gab2 significantly promoted the migratory of NSCLC cells. Finally, we found that Gab2 promotes NSCLC migration through the protein kinase B (Akt) signaling pathway and up-regulation the activity of matrix metallopeptidase (MMP)-2/9. To conclude, our findings suggest a novel mechanism underlying the migration of NSCLC cells which might serve as a new intervention target for the treatment of NSCLC.
Indexed as
Identifiers
27158407PMC4846964W2399050881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.